RUNX2 and metastatic prostate carcinoma: We have presented evidence that integration of two different signaling pathways (CD44 and αvβ3) facilitate osteoclastogenesis and bone loss via a RUNX2/Smad5/RANKL axis in metastatic prostate cancer cells.